



## Uptake of targeted therapies by income level, EGFRm+ NSCLC



Base sizes (number of patient record forms)	2015	2016	2017
<7,000 RMB/month	n=171	n=275	n=195
>10,000 RMB/month	n=185	n=270	n=397

Fig. 1: uptake of EGFR TKIs over time, based on EGFRm-positive NSCLC patient record forms collected across 17 cities in China, by monthly household income level. (Source: Ipsos China Oncology Monitor 2015 – 2017; research conducted through pen and paper diaries March 2015 – September 2017)